Free tool
FAERS Monitor: Topicort
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018594 or its brand name (Topicort, Desoximetasone). Reports on generic versions are filed under their own applications.
Reports
19,273
Serious
18,360
95% of reports
Hospitalization
7,313
Death reported
5,296
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective10,104
- pain9,142
- fatigue9,090
- rheumatoid arthritis8,445
- alopecia8,417
- systemic lupus erythematosus8,376
- pemphigus8,111
- abdominal discomfort8,037
- glossodynia7,884
- swelling7,357
- hand deformity7,164
- rash7,093
- arthropathy6,983
- drug intolerance6,872
- wound6,725
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 3 |
| 2006 | 10 |
| 2007 | 4 |
| 2008 | 12 |
| 2009 | 16 |
| 2010 | 19 |
| 2011 | 19 |
| 2012 | 45 |
| 2013 | 47 |
| 2014 | 64 |
| 2015 | 142 |
| 2016 | 269 |
| 2017 | 413 |
| 2018 | 520 |
| 2019 | 1,058 |
| 2020 | 2,045 |
| 2021 | 3,122 |
| 2022 | 2,964 |
| 2023 | 1,681 |
| 2024 | 3,180 |
| 2025 | 2,609 |
| 2026 | 1,027 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,034,886 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pemphigusSignal | 8,111 | 2010.6 | 1943.6 | 5,734,769 |
| hand deformitySignal | 7,164 | 1310.6 | 1270.2 | 4,261,716 |
| glossodyniaSignal | 7,884 | 592.4 | 578.7 | 3,020,097 |
| woundSignal | 6,725 | 345.3 | 337.3 | 1,756,051 |
| systemic lupus erythematosusSignal | 8,376 | 336.7 | 330.0 | 2,145,749 |
| arthropathySignal | 6,983 | 156.6 | 153.4 | 946,612 |
| swellingSignal | 7,357 | 93.0 | 91.2 | 619,755 |
| rheumatoid arthritisSignal | 8,445 | 87.6 | 86.1 | 672,926 |
| drug intoleranceSignal | 6,872 | 83.5 | 81.8 | 522,637 |
| abdominal discomfortSignal | 8,037 | 54.9 | 53.9 | 407,872 |
| alopeciaSignal | 8,417 | 48.8 | 48.0 | 380,897 |
| rashSignal | 7,093 | 18.0 | 17.7 | 114,632 |
| painSignal | 9,142 | 16.5 | 16.2 | 134,801 |
| fatigueSignal | 9,090 | 12.9 | 12.7 | 102,217 |
| drug ineffectiveSignal | 10,104 | 8.4 | 8.3 | 69,974 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.